Celecoxib, also known as Celebrex, is a non-steroidal anti-inflammatory drug (NSAID) that relieves pain and other symptoms of inflammation. It’s a trusted treatment for three types of arthritis: osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. In these conditions, it effectively alleviates pain, swelling, redness, and fever. It’s also a reliable option for menstrual cramps.
Celecoxib works by inhibiting an enzyme called cyclooxygenase-2, which plays a role in the production of prostaglandin, a molecule involved in pain and inflammation.
Dosage
Celecoxib is available in capsules. The usual dose is 400 mg initially, followed by 200 mg twice daily.
Common Side Effects
- Abdominal pain
- Constipation
- Diarrhea
- Flatulence
- Heartburn
- Nausea and vomiting
- Dizziness
- Headache
- Cough or sore throat
Cost of Celebrex
Celecoxib’s price varies from $9.00 to $60.00 with a coupon. Click here to find a pharmacy near you.
How to Obtain a Prescription for Celebrex
Celebrex (celecoxib) is a prescription drug that can be conveniently prescribed by a physician or other licensed prescriber. Did you know? QuickMD offers the convenience of refilling most medications remotely through telemedicine, including Celebrex. This means you can get your prescription without leaving your home.
Disclaimer
Articles on this website are meant for educational purposes only and are not intended to replace professional medical advice, diagnosis or treatment. Do not delay care because of the content on this site. If you think you are experiencing a medical emergency, please call your doctor immediately or call 911 (if within the United States). This blog and its content are the intellectual property of QuickMD LLC and may not be copied or used without permission.
QuickMD has strict referencing policies and relies on reputable sources, including peer-reviewed research, clinical guidelines, medical organizations, and government and public health agencies, among others. Learn more about how we ensure accuracy in our content by reading our editorial guidelines.
